查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611986

急性護理綜合症檢測市場：按疾病類型、目標、樣本類型和最終用戶 - 2025-2030 年全球預測

Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年，急性護理綜合症檢測市場價值為 34 億美元，預計到 2024 年將達到 37.4 億美元，複合年成長率為 9.99%，到 2030 年將達到 66.3 億美元。

急性護理症候群檢測是指使用診斷測試，同時檢測一個樣本中的多種病原體，並提供快速、全面的結果，這對於急性護理環境中的快速決策至關重要。感染疾病日益流行以及需要及時、準確的診斷以最佳化治療和改善患者的治療結果推動了對此類檢測的需求。其應用範圍廣泛，包括急診室、重症監護室和加護病房，其中快速病原體識別對治療通訊協定有重大影響。最終用途多種多樣，包括醫院、診斷中心和研究機構，展示了廣泛採用的潛力。

主要市場統計
基準年[2023] 34億美元
預測年份 [2024] 37.4億美元
預測年份 [2030] 66.3億美元
複合年成長率（%） 9.99%

市場成長受到分子診斷技術進步、人工智慧整合以增強預測分析以及人們對早期精確診斷益處的認知不斷增強等因素的影響。感染疾病率的上升、對創新診斷的監管支持以及醫療保健支出的增加進一步推動了需求。新的發展機會在於開發低成本攜帶式診斷設備，以及在偏遠和資源匱乏的地區擴大檢測範圍，在這些地區，獲得醫療保健服務是一項重大挑戰。

然而，市場面臨先進診斷工具成本高、監管要求嚴格以及測試標準化潛在問題等限制。此外，操作方面的挑戰也很多，因為需要訓練有素的人員來操作複雜的設備並解釋結果，這影響了採用率，特別是在發展中地區。

急性護理綜合症測試的創新應側重於提高測試特異性、縮短週轉時間以及將照護現場設備與數位健康平台相結合以促進遠端監控和諮詢。持續研究病原體的演化模式對於確保更新針對新出現威脅的有效診斷解決方案至關重要。在技​​術進步和不斷變化的醫療保健需求的推動下，市場格局是動態的。這表明相關人員支持創新、進行公共衛生工作合作以及解決市場滲透障礙的環境已經成熟。

市場動態：快速發展的急性護理症候群檢測市場的關鍵市場洞察

供需的動態交互作用正在改變急性護理綜合症檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病爆發增加
    • 利用綜合症測試來檢測抗菌藥物抗藥性
    • 政府擴大性行為感染傳染病治療和診斷的舉措
  • 市場限制因素
    • 假陽性/假陰性的發生與污染的可能性
  • 市場機會
    • 努力將症狀檢測納入管理計劃
    • 臨床微生物學的進步導致檢測策略的改進
  • 市場挑戰
    • 急性醫學綜合症檢測方法的技術局限性

波特五力：駕馭急診症候群偵測市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解急性照護症候群檢測市場的外部影響

外部宏觀環境因素在塑造急性護理症候群檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解急性醫學症候群檢測市場的競爭狀況

急性護理綜合症測試市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣急性護理症候群測試市場供應商的績效評估

FPNV 定位矩陣是評估急性護理症候群檢測市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為急診症候群檢測市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對急性護理綜合症檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病率增加
      • 使用症狀測試檢測抗菌藥物抗藥性
      • 政府努力擴大性行為感染傳染病的治療和診斷
    • 抑制因素
      • 假陽性和陰性的發生率以及污染的可能性
    • 機會
      • 將綜合症測試納入管理計劃的努力
      • 臨床微生物學的進步改進了檢測策略
    • 任務
      • 急性護理綜合症檢測方法的技術局限性
  • 市場區隔分析
    • 疾病類型：污染程度的增加和氣候模式的變化導致呼吸道疾病的盛行率急劇上升
    • 目標：需要及時、快速診斷急診環境中的細菌感染疾病
    • 樣本類型：利用血液樣本促進感染疾病和敗血症的檢測
    • 最終用戶：增加私人投資和政府努力升級醫院基礎設施
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 急性醫學症狀檢測市場：依疾病類型

  • 消化系統疾病
  • 泌尿系統疾病
  • 呼吸系統疾病
  • 熱帶疾病

第7章 急性醫學症狀檢測市場目標

  • 細菌
  • 真菌
  • 寄生蟲
  • 病毒

第8章依樣本類型分類的急診症候群檢測市場

  • 生物體液
  • 血
  • 凳子
  • 棉花棒
  • 尿

第9章 急性醫學症候群檢測市場：依最終使用者分類

  • 臨床和診斷實驗室
  • 醫院
  • 研究/學術機構

第10章美洲急性醫學症檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區急性醫學症候群檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的急性醫學症候群檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准針對 COVID-19 的家庭抗原測試
    • 拜登政府提供美國家庭免費新冠病毒檢測，向國內製造商投資6億美元
    • NIH 推出居家測試作為 COVID-19遠端醫療計劃試點
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Applied BioCode, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • BIOHM Health LLC
  • bioMerieux SA
  • Curetis GmbH by OpGen, Inc
  • CVS Health
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Genetic Signatures Ltd.
  • Hologic Inc.
  • Luminex Corporation
  • Microbiologics, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market was valued at USD 3.40 billion in 2023, expected to reach USD 3.74 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 6.63 billion by 2030.

Acute care syndromic testing refers to the use of diagnostic tests that simultaneously detect multiple pathogens from a single sample, offering rapid and comprehensive results essential for quick decision-making in acute care settings. This testing is necessary due to the increasing prevalence of infectious diseases and the need for timely and accurate diagnosis to optimize treatment and improve patient outcomes. Applications are wide-ranging, including emergency rooms, urgent care, and intensive care units, where rapid pathogen identification can significantly impact treatment protocols. The end-use scope spans hospitals, diagnostic centers, and research institutes, underscoring its broad adoption potential.

KEY MARKET STATISTICS
Base Year [2023] USD 3.40 billion
Estimated Year [2024] USD 3.74 billion
Forecast Year [2030] USD 6.63 billion
CAGR (%) 9.99%

Market growth is influenced by factors such as advancements in molecular diagnostic technologies, the integration of AI for enhanced predictive analytics, and growing awareness about the benefits of early and precise diagnostics. The rising incidence of infectious outbreaks, regulatory support for innovative diagnostics, and increasing healthcare spending further drive demand. Emerging opportunities lie in developing low-cost, portable diagnostic devices and expanding testing into remote and resource-poor settings, where accessibility significantly challenges healthcare delivery.

However, the market faces limitations such as high costs of advanced diagnostic tools, stringent regulatory requirements, and potential issues with test standardization. Moreover, the necessity for trained personnel to operate sophisticated equipment and interpret results adds to operational challenges, impacting adoption rates, especially in developing regions.

Innovation in acute care syndromic testing should focus on enhancing test specificity, reducing turnaround times, and integrating point-of-care devices with digital health platforms to facilitate remote monitoring and consultation. Continuous research into pathogen evolution patterns is essential to ensure effective diagnostic solutions remain updated for emerging threats. The nature of the market is dynamic, driven by technological advancements and evolving healthcare needs, indicating a vibrant landscape ripe for stakeholders to support innovation, collaborate on public health initiatives, and tackle the barriers hindering widespread market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Care Syndromic Testing Market

The Acute Care Syndromic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of infectious disease outbreaks
    • Utilization of syndromic tests for detecting antimicrobial resistance
    • Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
  • Market Restraints
    • Incidences of false positives and false negatives and chances of contamination
  • Market Opportunities
    • Efforts to include syndromic testing under stewardship programs
    • Advancements in clinical microbiology leading to improved testing strategies
  • Market Challenges
    • Technical limitations of acute care syndromic testing methods

Porter's Five Forces: A Strategic Tool for Navigating the Acute Care Syndromic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Care Syndromic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Care Syndromic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Care Syndromic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Care Syndromic Testing Market

A detailed market share analysis in the Acute Care Syndromic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Care Syndromic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Care Syndromic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Care Syndromic Testing Market

A strategic analysis of the Acute Care Syndromic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases, and Tropical Diseases.
  • Based on Target, market is studied across Bacteria, Fungi, Parasites, and Viruses.
  • Based on Sample Type, market is studied across Biofluids, Blood, Stool, Swabs, and Urine.
  • Based on End User, market is studied across Clinical & Diagnostic Laboratories, Hospitals, and Research & Academic Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious disease outbreaks
      • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
      • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
      • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations of acute care syndromic testing methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Care Syndromic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal Diseases
  • 6.3. Genitourinary Diseases
  • 6.4. Respiratory Diseases
  • 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

  • 7.1. Introduction
  • 7.2. Bacteria
  • 7.3. Fungi
  • 7.4. Parasites
  • 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Biofluids
  • 8.3. Blood
  • 8.4. Stool
  • 8.5. Swabs
  • 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical & Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Clears COVID-19 Home Antigen Test
    • 13.3.2. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
    • 13.3.3. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Applied BioCode, Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Biocartis NV
  • 6. BIOHM Health LLC
  • 7. bioMerieux SA
  • 8. Curetis GmbH b y OpGen, Inc
  • 9. CVS Health
  • 10. Danaher Corporation
  • 11. DiaSorin S.p.A
  • 12. Eurofins Scientific SE
  • 13. F. Hoffmann-La Roche Ltd
  • 14. Genetic Signatures Ltd.
  • 15. Hologic Inc.
  • 16. Luminex Corporation
  • 17. Microbiologics, Inc.
  • 18. Pfizer, Inc.
  • 19. QIAGEN N.V.
  • 20. QuantuMDx Group Ltd.
  • 21. Seegene Inc.
  • 22. Siemens Healthineers AG
  • 23. Sysmex Corporation
  • 24. Thermo Fisher Scientific Inc.
  • 25. Werfen

LIST OF FIGURES

  • FIGURE 1. ACUTE CARE SYNDROMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE CARE SYNDROMIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023